Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 13/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11896985 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL11897000 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL372639 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL372640 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL29749473 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL6523113 | 0.99 | CHRNB2 (0.98) | CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL6523106 | 0.99 | CHRNB2 (0.98) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL372948 | 0.90 | CHRNB2 (0.82) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL372829 | 0.89 | CHRNA7 (0.79) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL372958 | 0.89 | CHRNA7 (1.00) | CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | claimed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2647373-A1 | Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine. | Targacept, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2409703-A1 | Treatment with alpha7-selective ligands | Targacept, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2364150-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | Targacept Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110098312-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | Targacept ,Inc (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2296640-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | Targacept Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010056622-A1 | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2185152-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | Targacept Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009140201-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | TARGACEPT, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009018511-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | CHRNB2 6/4885CHRNA4 3/4885CHRNA7 1/4885 |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | CHRNA7, CHRNA1, CHRNG | CHRNB2 17/4885CHRNA4 9/4885CHRNA7 1/4885 |
| US-20110098312-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | CHRNA10, CHRNA5, CHRNB2 | CHRNB2 3/4885CHRNA4 10/4885CHRNA7 6/4885 |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | CHRNA7, CHRNA4, CHRNA2 | CHRNB2 6/4885CHRNA4 2/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.